Corix Bioscience, Inc. acquired Pharmaceutical Development Company Ltd from Sentinelle Global Investments (Proprietary) Limited, David Lamont Manaway, Clifford Elphick and Maria Elisabeth Findt for $2.2 million.
November 06, 2017
Share
Corix Bioscience, Inc. (OTCPK:CXBS) agreed to acquire Pharmaceutical Development Company (Pty) Ltd from Sentinelle Global Investments (Proprietary) Limited, David Lamont Manaway, Clifford Elphick and Maria Elisabeth Findt for $2.2 million on October 30, 2017. Corix Bioscience issued 1.3 million shares of its restricted stock and paid $0.2 million as purchase consideration. On October 30, 2017, the Board of Corix Bioscience, Inc. approved the transaction. The Chesapeake Group acted as broker to the transaction.
Corix Bioscience, Inc. (OTCPK:CXBS) completed the acquisition of Pharmaceutical Development Company (Pty) Ltd from Sentinelle Global Investments (Proprietary) Limited, David Lamont Manaway, Clifford Elphick and Maria Elisabeth Findt on November 1, 2017.
Corix Bioscience, Inc., formerly American Housing Income Trust, Inc., is an organic biotechnology company. The Company is engaged in providing cannabidiol (CBD) oil, which is used for a wide variety of medicinal purposes. It is also engaged in cultivating and extracting tetrahydrocannabivarin (THCV) oil. It clones all of its plants based off of three original types: Otto, Cherry Wine and Georges Pet. It operates in Oregon, California and Nevada, United States.
Corix Bioscience, Inc. acquired Pharmaceutical Development Company Ltd from Sentinelle Global Investments (Proprietary) Limited, David Lamont Manaway, Clifford Elphick and Maria Elisabeth Findt for $2.2 million.
CORIX BIOSCIENCE, INC. 
